[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"systolic-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:systolic-dysfunction":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100630712","rhythm-and-myocardial-function-relationship-evaluation-in-heart-diseases-100630712",false,"NCT07491237","RHYthm and Myocardial Function Relationship Evaluation in Heart Diseases","RHYME-HD","Inclusion Criteria:\n\n* Only patients aged \\> 18 years with a history of arrhythmia warranting non-pharmacological treatment according to the guidelines will be selected.\n* Collection of informed consent for the prospective cohort.\n* For the retrospective cohort, the Promoter has carried out a Data Protection Impact Assessment (DPIA), which ascertained the adequacy of the technical and organisational measures adopted to ensure the protection of the fundamental rights and freedoms of data subjects, in accordance with Article 89 of Regulation (EU) 2016\u002F679 and the guidelines of the Data Protection Authority. Data processing will be limited to the purposes of the study and conducted in accordance with the principles of minimisation, pseudonymisation and security, in compliance with the guarantees defined by the Data Protection Authority.\n\nExclusion Criteria:\n\n* Patients who, upon initial assessment at our centre, do not present arrhythmias that would indicate non-pharmacological treatment.\n* Patients for whom it is not possible to obtain adequate medical history and\u002For follow-up through medical examination or telephone consultation.\n* Refusal to give informed consent to participate in the study.","ALL","18 Years",{"count":19,"type":20},253,"ESTIMATED","OBSERVATIONAL","Arrhythmias are widespread among the global population. Although they can occur in healthy hearts, they are often the manifestation of a hereditary or acquired heart muscle disease, and may be the cause or, more often than not, the consequence.\n\nIn recent decades, with advances in medical knowledge and technology, non-pharmacological therapies for arrhythmias have become increasingly popular. These fall into two broad categories: therapies aimed at electrostimulation and those aimed at ablation of arrhythmias.\n\nThe selection of patients eligible for these procedures is essential for the effectiveness of the therapy, the reduction of complications and the optimisation of resources.\n\nNot all patients, even those selected according to guidelines, respond equally to the chosen therapy. Other patients, due to their clinical\u002FECG characteristics, do not have clear indications and remain in a borderline area where the class of evidence and\u002For recommendation of the guidelines is less stringent. Still others develop recurrences or complications during follow-up that require further intervention.\n\nIn this context, it is essential in the study of these patients not only to use standard instrumental examinations, such as echocardiograms, Holter ECGs and stress tests (simple and cardiopulmonary), but also and above all to use advanced imaging methods (STE, 3D echo, MRI, CT, PET-CT) and remote monitoring tools that integrate diagnostic algorithms managed by artificial intelligence.\n\nIn light of these considerations, our project consists of conducting an observational study that includes all patients with arrhythmias who are candidates for electrostimulation and\u002For ablation procedures at the Arrhythmology Unit and\u002For followed up at the Arrhythmology Clinic of our Polyclinic, in order to assess the clinical and\u002For imaging characteristics associated with a worse prognosis in this population, in terms of response to therapy and development of complications. Our main aim is to identify, within the above-mentioned population, the subgroups of responder patients versus non-responder patients, i.e. those with a worse prognosis , who deserve greater attention and more frequent follow-up.",[24,25,26,27,28,29,30],"Arrhythmia","Cardiomyopathy, Dilated","Systolic Dysfunction","Atrial Fibrillation","Ventricular Arrythmia","Heart Failure","Cardiomyopathies","NOT_YET_RECRUITING","2026-03-18",{"date":34,"type":35},"2026-03-24","ACTUAL",{"date":37,"type":20},"2026-04-15",{"date":39,"type":20},"2031-12-31",{"name":41,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100479135","cardiac-contractility-modulation-in-chagas-heart-disease-100479135","NCT05519046","Cardiac Contractility Modulation in Chagas Heart Disease","Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease: a Randomized Study - Contractility - FIX-Chagas","FIX-Chagas","Inclusion Criteria:\n\n* Signing of an informed consent form (ICF) before randomization and any study procedure,\n* Both genders, age \\>18 years and \\\u003C75 years,\n* Recent positive (last two years) and documented serology for Chagas disease, in at least two different tests (indirect hemagglutination, indirect immunofluorescence, or ELISA),\n* NYHA II-III heart failure functional class,\n* LVEF\\\u003C 35%,\n* Non left bundle branch block\n* Intraventricular desynchrony (Yu index)\n* Global longitudinal strain \\>11 %.\n\nExclusion Criteria:\n\n* Participation in another study, presently or terminated \\\u003C1 year ago, except for a totally unrelated observational study,\n* Other concomitant cardiovascular diseases, including uncontrolled diabetes mellitus (systemic arterial hypertension without permitted target organ compromise),\n* Kidney dysfunction (serum creatinine \\>1.5mg\u002FdL or eGFR \\\u003C30mL\u002Fmin\u002F1.73m2) or liver dysfunction, with diagnosis of cirrhosis or portal hypertension or elevated serum enzymes (AST or ALT) \\> 3x the upper limit of normality,\n* Moderate or severe chronic obstructive pulmonary disease,\n* Peripheral polyneuropathy,\n* Hyperthyroidism,\n* Current alcoholism or not abandoned for \\>2 years,\n* Diagnosed with psychopathy or psychosis or addiction to illicit drugs,\n* Life expectancy \\\u003C1 year, due to the disease itself or comorbidities (including NYHA class IV),\n* Pregnancy or breastfeeding,\n* Potential to become pregnant during the study (non-menopausal patients who have not undergone a radical and safe contraceptive process),\n* Previously withdrawn from this study.","75 Years",{"count":53,"type":20},60,"INTERVENTIONAL",[56],"NA","Chagas disease is an endemic problem in Latin America, where millions of people are chronically infected with T. cruzi. Recently, it was assumed to have clinical and epidemiological relevance in several other countries due to migratory and globalizing social factors. CCC occurs in 30-50% of infected individuals, causing considerable morbidity\u002Fmortality rates. Heart failure is the most prevalent morbidity. While CRT and drug treatment have been advocated and implemented without much success to improve the clinical condition of patients with CCC, there is no consistent scientific evidence on the role of cardiac contractility modulation (CCM) as a form of adjuvant treatment for heart failure in patients with CCC.\n\nThe hypothesis of this study is that patients with CCC, advanced heart failure, severe systolic dysfunction, and non-LBB have better clinical and functional responses when undergoing implantation of a CCM device than when undergoing cardiac resynchronization therapy.",[59,29,26,60,61],"Chagas Cardiomyopathy","Right Bundle Branch Block and Left Anterior Fascicular Block","Right Bundle Branch Block and Left Posterior Fascicular Block","RECRUITING","2025-04-02",{"date":65,"type":35},"2025-04-04",{"date":67,"type":35},"2022-05-25",{"date":69,"type":20},"2026-12-31",{"name":71,"class":42},"InCor Heart Institute",1]